CCL5 and posterior cortical atrophy: Moreover, ICA has been identified as a promising immunomodulator for metastatic prostate cancer (PCa) bone metastasis, as it significantly reduces PCa metastasis-induced bone destruction in vivo by inhibiting osteoclastogenesis through downregulation of the TAM/CCL5 pathway (Chen et al., 2023).